Vancouver, British Columbia--(Newsfile Corp. - July 3, 2015) - New York based SeeThruEquity has initiated coverage on M Pharmaceutical (CSE: MQ). On June 15th the company was approved for trading on the OTCQB under the symbol MPHMF, which SeeThruEquity believes will expand the company's potential institutional shareholder base. Analyst Amit Tandon gives M-Pharma a target price of $0.79, a premium of 316% to the $0.19 price on June 24th, the day the report was issued.

InvestmentPitch.com has produced a "short video summary" about M Pharma based on this report. If this link is not enabled, please visit www.InvestmentPitch.com and enter "M Pharma" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_gwy5t40n/SeeThruEquity-has-initiated-coverage-on-M-Pharmaceutical-CSE-MQ

Based in Vancouver, Canada, M Pharma is a new, development stage biomedical company focused on developing solutions to improve the health and quality of life for people suffering from obesity and diabetes.

The company has exclusive rights to an innovative family of biomedical technologies including:
1) Trimeo weight loss capsules;
2) Trimtec gastric management system, intended to deliver a "realistic, patient centered" approach with reduced invasiveness; and
3) eMosquito, a wearable blood monitor that utilizes novel micro-electromechanical technology for automatic and autonomous monitoring of blood glucose levels.

Given that M Pharma is a development stage enterprise targeting a large potential market, SeeThruEquity views its management team as core to any investment thesis.

On April 15th, M Pharma announced that medical technology pioneer Dr. Martin Mintchev accepted the position as President and CEO. Dr. Mintchev brings a wealth of industry expertise and leadership experience to the company, as well as a deep understanding of M Pharma's innovative family of biomedical technologies, having been the primary developer of the medical technologies held by M Pharma.

The company recently added Douglas Janzen to its Scientific Advisory Board. Janzen is cofounder and managing partner of Northview Ventures and has completed over $1 billion in equity financing and over $1 billion in licensing deals in the biotechnology sector.

Analyst Amit Tandon stated: "We see tremendous potential for M Pharma if it can successfully develop and achieve clearance for its promising family of biomedical technologies. The Global weight management market is expected to rise from $148.1 billion in 2014 to $206.4 billion in 2019. Similarly, Frost & Sullivan has estimated the global market for blood glucose products to be $8.67 billion per year."

The shares are currently trading at $0.14, well below the target price of $0.79 and with 27.8 million shares outstanding, the company is capitalized at $3.9 million.

For more information about M-Pharma, please visit the company's website www.m-pharma.ca, call 604-428-0511 or email info@m-pharma.ca.

For more information about SeeThruEquity or to obtain a copy of their research report, please visit the company's website www.seethruequity.com or contact Amit Tandon at 646-495-0939 or email amit@seethruequity.com.

About InvestmentPitch

InvestmentPitch.com is a leading international producer and distributer of specialized video content for the investment community. The company specializes in producing three minute videos based on news releases, research reports and other news of interest to investors.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com